January 19th 2023
Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), antiretroviral drugs used to treat HIV and hepatitis B, may be simultaneously depleting the energy of immune cells.
December 20th 2022
A central portal to support clinical practice for patients with or at risk for HIV was launched.
December 19th 2022
Genital herpes (HSV-2) affects quality-of-life but also causes substantial economic losses, especially in low- and middle-income countries.
December 16th 2022
A new CDC report highlights another health-related area where interruptions occurred due to the pandemic, but data suggests both improved rapidly.
Europe’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Triumeq PD, the first dispersible single tablet regimen with dolutegravir, for children living with HIV.
If Priced Right, Long-Acting Injectable Cabotegravir Could Reduce Spread of HIV
For this to be a viable HIV reduction strategy, scale-up demand creation should be coordinated between all partners, the study authors said, and should be fast enough to build momentum and yield the expected results.
Significant Barriers Keep Patients from Adopting Injectable PrEP
The study showed, however, that physicians can help solve the problem if they are willing to answer patient’s questions about the therapy’s efficacy and safety.
Infectious Disease Update: This Week's Top Stories
Read and watch the infectious disease trial data shared this week.
Opinions of Oral Versus Injectable HIV PrEP in a Racially Diverse Cohort
Concerns of injectable HIV PrEP safety and efficacy demonstrate a need for health care providers to share reliable information with at-risk populations.
Has HIV PrEP Uptake Increased Among High-Risk Persons?
Although HIV PrEP uptake is gradually increasing, usage remains low among key at-risk populations.
Do People Who Inject Drugs Use HIV PrEP?
HIV PrEP prescriptions increased from 0 among people who use injection drugs, but overall PrEP uptake remains low.
Quantifying HIV Stigma Among Hispanic and Latino Populations
The study authors called eliminating barriers to HIV care and treatment a national priority.
Dolutegravir Effectively Suppresses HIV in Pregnant Women
Pregnant people taking dolutegravir were more likely to achieve HIV viral suppression and less likely to have a preterm birth than participants using other forms of ART.
HIV and Aging in the Era of Antiretroviral Therapy: Considerations in Clinical Care
With the population of adults with HIV growing older, incorporating age-based
screenings, comprehensive assessments, and morbidity management into
routine HIV care is essential in improving health outcomes and quality of life.
Potential Cure for HIV from CRISPR Gene Editing in Phase 1/2 Clinical Trial
CRISPR edit of proviral DNA tested as potential cure for HIV in first participant of phase 1/2 clinical trial.
The Top Infectious Disease Stories This Week
Articles covering respiratory infections were our most-clicked this week.
HIV PrEP Stigma Persists, Even Among Men Who Have Sex With Men
Among male couples, HIV PrEP usage is suboptimal. Lingering stigma may be preventing men who have sex with men from using PrEP, even when in a relationship with an HIV-positive partner.
Improving Tuberculosis Prevention Programs Aimed at HIV Patients
The intervention included meeting with experts, texting services to improve and facilitate communication, and data collection and dissemination.
Merck Initiates a Phase 3 Program for Islatravir
This will include 3 trials to examine the therapy in different formulations in HIV studies.
Gender-Affirming Care in Persons Living With HIV
Gender-affirming hormone therapy (GAHT) therapy consists of administration of exogenous hormones and suppression of endogenous hormone production, with the goal of obtaining characteristics more congruent with an individual’s gender identity. Here is a review of these therapies and consideration for PrEP and the risks associated with HIV in this diverse population.
HIV Prevalence High Among Female Sex Workers But Interventions Have Positive Effect
There are a number of programs designed to help lower rates of infection and transmission amongst this industry's workforce in South Africa.
Tracking the Lifespan of HIV Host Cells
Investigators noted 2 distinct phases of HIV virus levels, meaning any infected cells that survive treatment can become latent, only to reignite HIV infection after antiretroviral therapy is stopped.
A Study of HIV and STIs Among People With Monkeypox
Texas Judge Rules Employers Shouldn’t Be Required to Cover HIV PrEP
Texas judge Reed O’Connor ruled that requiring employers to cover the medical expense of HIV PrEP is a violation of religious freedom.
Lenacapavir, Gilead’s Long-Acting HIV Treatment, Approved in Europe
The European Commission approved lenacapavir to treat multidrug-resistant HIV infection. The long-acting HIV treatment regimen will be marketed as Sunlenca and available in injection or tablet form.
HIV Associated with Rapid Age Acceleration, New Study Finds
The study was longitudinal in nature, comparing at-risk people who became infected with HIV to at-risk people who did not.
Incidence of STIs Stabilized Among Gay and Bisexual Men Using HIV PrEP
After widespread implementation of HIV pre-exposure prophylaxis (PrEP) among gay and bisexual men in Australia, population-level incidence of chlamydia and gonorrhea stabilized, allaying fears that PrEP would lead to a rise in STIs, a recent study found.
Biktarvy Effective for HIV Patients Coinfected With Hepatitis B
At AIDS 2022, Gilead presented data suggesting Biktarvy was a safe and effective complete HIV treatment regimen, including for those coinfected with hepatitis B.
PrEP State of the Union: Adherence, Access, Uptake Issues
Although this form of prophylaxis is highly protective, there are situations
in which breakthrough infections occur.
New Treatment for HIV, Visceral Leishmaniasis Coinfection
Visceral leishmaniasis patients coinfected with HIV are vulnerable to other comorbidities including tuberculosis and cryptococcal meningitis but also to degrees of stigmatization and human rights issues.
EMA Moves Forward with Recommendation for Lenacapavir based on 26-Week Data
A positive recommendation now heads to the European Commission, which can grant marketing authorization for 27 European Union member states.
HIV Testing and Diagnoses Drop During COVID-19 Pandemic
The commitment to ending the HIV epidemic endures, despite drops in testing and new diagnoses during the COVID-19 pandemic.
Treating HIV Patients’ Precancerous Growths Reduces Anal Cancer by Half
In a phase 3 trial, if HIV patients received treatment for precancerous HSILs, their risk for developing anal cancer was reduced by half.
Combination bNAbs Therapy Could Eventually Replace Daily ART
This small study had 2 phases, but patients saw HIV viral suppression for about 40 weeks after receiving the combination therapy infusions.
INSTIs and Cardiovascular Risk for HIV Patients
INSTIs have been thought to contribute to weight gain and metabolic syndrome, which in turn may contribute to cardiovascular events in HIV patients.
2 Clarke Drive Cranbury, NJ 08512